Trials / Completed
CompletedNCT05826275
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Toragen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TGN-S11 | Small Molecule |
| DRUG | Pembrolizumab | PD-1 checkpoint blockade |
Timeline
- Start date
- 2023-06-20
- Primary completion
- 2025-05-28
- Completion
- 2025-06-28
- First posted
- 2023-04-24
- Last updated
- 2025-09-09
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05826275. Inclusion in this directory is not an endorsement.